Webinars starting with O

Pharma’s investment in digital has grown significantly in the last few years, fueled by the proliferation of digital channels and evolving customer preferences. This has made customer journeys very complex, with customers choosing how and where to interact with your brand in a unique and on-demand manner. With these trends in play, we must ensure a holistic measurement approach towards measuring and optimizing omnichannel campaigns.

In this webinar, we discuss orchestrating various analytical approaches, such as Marketing Mix Modeling, attribution modeling, and campaign analytics in tandem at varying cadences to enable outcomes-driven omnichannel campaigns. We will also discuss how Marketing Mix outputs must evolve to inform downstream Next Best Action recommendations.

Oncology has become one of the top therapeutic areas for the pharmaceutical and biotechnology industries and global spending is expected to approach $200 billion within the next 3 years. The industry must contend with a variety of elements that are increasingly complex including rapid changes in treatment standards and pathways driven in part by assimilation of new technologies and biomarkers. Forecasting design and development considerations for oncology were discussed in a prior webinar.

In this follow-up webinar, we will discuss data sources to support epidemiology-based oncology forecasting approaches. Data will be reviewed in terms of publicly available sources to address unique elements of oncology forecasts including epidemiology data, staging and treatment data. Additionally, securing and integrating data related to patient subsets and survival proxies will be discussed and examples of how to review, vet and integrate data will be reviewed. Live examples using SEER data will be demonstrated and challenges for alignment between data sources will be discussed. Examples of a health system epi-based model constructed using data inputs for staging, treatment, patient-subset and regimen-based progression curves will be demonstrated.

Presenters:

• Bernie Manente, Foster Rosenblatt and Xin Hang, Senior Director, Foster Rosenblatt

Oncology has become one of the top therapeutic areas for the pharmaceutical and biotechnology industries and global spending is expected to approach $200 billion within the next 3 years. The industry must contend with a variety of elements that are increasingly complex including rapid changes in treatment standards and pathways driven in part by assimilation of new technologies and biomarkers. Forecasting in this complex environment can be fraught with many pitfalls and choosing the proper approach is driven by a number of considerations related to your product, your oncology portfolio and your organization.

In this webinar, we will demonstrate considerations for developing forecasts for oncology therapeutics. Attendees will learn from real-world examples how to utilize best practices for forecast development and discuss the options for securing data to support the alternative approaches. Additionally, we will discuss elements that can have the greatest impact on forecasts and offer guidance on how to secure internal alignment on these forecasts.

Presenters:

• Bernie Manente, Foster Rosenblatt